| Width: | 250px |
| Cas Number: | 2121525-08-2 |
| Unii: | HN0VIB0W8W |
| Pubchem: | 153420471 |
| Chemspiderid: | 58794254 |
| Kegg: | D11864 |
| Chembl: | 4594380 |
| Synonyms: | CIN-102; deuterated domperidone; domperidone deuterated |
| Iupac Name: | 3-[3-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propyl]-4,5,6,7-tetradeuterio-1H-benzimidazol-2-one |
| C: | 22 |
| H: | 20 |
| D: | 4 |
| Cl: | 1 |
| N: | 5 |
| O: | 2 |
| Smiles: | [2H]C1=C(C(=C2C(=C1[2H])NC(=O)N2CCCN3CCC(CC3)N4C5=C(C=C(C=C5)Cl)NC4=O)[2H])[2H] |
| Stdinchi: | 1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)/i1D,2D,4D,5D |
| Stdinchikey: | FGXWKSZFVQUSTL-GYABSUSNSA-N |
Deudomperidone (developmental code name CIN-102; also known as deuterated domperidone) is a dopamine antagonist medication which is under development in the United States for the treatment of gastroparesis.[1] [2] [3] It acts as a selective dopamine D2 and D3 receptor antagonist and has peripheral selectivity. Deudomperidone is a deuterated form of domperidone, and it is suggested that deudomperidone may have improved efficacy, tolerability, and pharmacokinetics compared to domperidone. As of January 2022, deudomperidone is in phase 2 clinical trials for the treatment of gastroparesis.